Provided by Tiger Fintech (Singapore) Pte. Ltd.

Stoke Therapeutics, Inc.

8.60
+0.49006.04%
Post-market: 8.600.00000.00%18:17 EDT
Volume:876.96K
Turnover:7.50M
Market Cap:455.52M
PE:-4.16
High:8.72
Open:8.18
Low:8.18
Close:8.11
Loading ...

Biogen Inc - Phase 3 Study of Zorevunersen to Initiate in Q2 2025

THOMSON REUTERS
·
18 Feb

Biogen Inc - Stoke Retains Exclusive Rights for Zorevunersen in US, Canada, Mexico; Biogen Gets Rest of World

THOMSON REUTERS
·
18 Feb

Biogen and Stoke Therapeutics Enter Into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated With Refractory Seizures and Neurodevelopmental Impairments

THOMSON REUTERS
·
18 Feb

Biogen Inc - Stoke to Receive $165M Upfront, up to $385M in Milestones

THOMSON REUTERS
·
18 Feb

Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength?

Zacks
·
05 Feb

The 13% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 116%

Simply Wall St.
·
27 Jan

Possible Signal As Stoke Therapeutics Insiders Sell US$523k In Stock

Simply Wall St.
·
22 Jan

Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

Zacks
·
17 Jan

Stoke Therapeutics negative reaction after STK-001 update overdone, says Chardan

TIPRANKS
·
08 Jan

Stoke Therapeutics Reports Alignment With Regulators for Dravet Syndrome Trial

MT Newswires Live
·
08 Jan

Wedbush Raises Stoke Therapeutics' Price Target to $19 From $17, Keeps Outperform Rating

MT Newswires Live
·
07 Jan

BRIEF-Stoke Therapeutics Plans To Initiate Phase 3 Study Of Zorevunersen To Treat Dravet Syndrome On Alignment With Global Regulatory Agencies

Reuters
·
07 Jan

Stoke Therapeutics finalizes EMPEROR study program with regulatory agencies

TIPRANKS
·
07 Jan

Stoke Therapeutics Announces Alignment With Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

THOMSON REUTERS
·
07 Jan

Stoke Therapeutics : FDA Breakthrough Therapy Designation Positions Zorevunersen on Efficient Development Path; Plans to Start Phase 3 in Mid-2025

THOMSON REUTERS
·
07 Jan

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Business Wire
·
07 Jan